Table 1:
Main demographic and clinical characteristics of cases and controls at study entry and the end of follow-up.
| Characteristics | Cases (n = 22) | Controls (n = 28) |
|---|---|---|
| Patients | ||
| Female, n (%) | 12 (54.5) | 13 (46.4) |
| Age (years), median (range) | 58.39 (38–78) | 63.2 (22–81) |
| Vaccinations, n (%) | ||
| 2 doses | 0 (0) | 6 (21.4) |
| 3 doses | 18 (81.2) | 17 (60.7) |
| 4 doses | 4 (18.8) | 5 (17.9) |
| B-cell depleted at study enrolment | 10 (45) | 12 (42.9) |
| IgG level (U/L), mean ± SD at study enrolment | 871 ± 67 | 907 ± 57 |
| eGFR (ml/min/1.73 m2), mean ± SD at study enrolment | 57 ± 21 | 61 ± 26 |
| Diagnosis, n (%) | ||
| Membranous glomerulonephritis | 7 (31.8) | 7 (25.0) |
| ANCA-associated vasculitis | 4 (18.2) | 4 (14.3) |
| Focal segmental glomerulosclerosis | 5 (22.7) | 3 (10.7) |
| Lupus nephritis | 4 (18.2) | 1 (3.6) |
| IgAN | 1 (4.5) | 2 (7.1) |
| Other glomerulopathiesa | 1 (4.5) | 11 (39.3) |
| Outcomes, n (%) | ||
| Symptomatic COVID-19 infection | 0 (0) | 11 (39.3) |
| Hospitalisation | 0 (0) | 2 (18.2) |
| Mortality | 0 (0) | 0 (0) |
aThrombotic thrombocytopenic purpura, minimal change disease, immunoglobulin M glomerulonephritis, membranoproliferative glomerulonephritis, immunotactoid glomerulonephritis, cryoglobulinaemic vasculitis.
IgG: immunoglobulin G; eGFR: estimated glomerular filtration rate; IgAN: immunoglobulin A nephropathy.